SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Paracelsian Inc (PRLN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: paul goldstein who wrote (431)9/8/1996 8:50:00 PM
From: WWS   of 4342
 
Paul, awhile back we were discussing costs of developing drugs. I found an article about AIDs drugs in the July 14 issue of NY Times, and include here a paragraph from it to illustrate the true magnitude of the task confronting PRLN either with PN355 or PN27,1.
"John Doorley is Merck's executive director of corporate communications...
...Why, I ask Doorley, are AIDS drugs, including Merck's indinavir, so
expensive? ''We screened more than 23,000 compounds and brought five drugs
into human trials,'' he says. ''We've invested more than $400 million on our
total AIDS research program. We've had to build a new factory in Virginia.''
And no company ever shows books and figures to prove their case, he adds. That
information would be too useful to competitors."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News